Search
for
Sort by
Research 91–120 of 105
- Dermatologic Adverse Events from Cancer Treatments
- Logic-based modeling and drug repurposing for the prediction of novel therapeutic targets and combination regimens against E2F1-driven melanoma progression
- Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
- Keratosis pilaris
- Dermoscopy to the rescue
- Manifestation of pityriasis amiantacea following initiation of minoxidil
- Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems
- Targeting the Warburg Effect in Anaplastic Thyroid Carcinoma: Metabolic Vulnerabilities and Therapeutic Opportunities
- Research Progress on Construction Technology of 3D Human Skin Models and Its Application Prospects in Dermatology
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Multi-omics analysis unveils the role of cancer-associated fibroblasts in cutaneous squamous cell carcinoma
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Ponatinib-induced pityriasis rubra pilaris-like adnexal dysmaturation: A case report
- Research advances of tissue-derived extracellular vesicles in cancers
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- RASopathic Skin Eruptions during Vemurafenib Therapy
- RASopathic alopecia: Hair changes associated with vemurafenib therapy
- Vemurafenib-induced pityriasis amiantacea: a case report
- Correction: RASopathic Skin Eruptions during Vemurafenib Therapy
- Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma
- Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
- Cutaneous toxicities of new treatments for melanoma
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
- 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma
- 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
- Targeted therapy in melanoma
- Updates from the British Association of Dermatologists 91st Annual Meeting, 5-7 July 2011, London, U.K.
- Biological therapy in the treatment of melanoma
- 559 Visualization of sweat suppression following botulinum toxin A by soluble microneedle arrays